6-chloro-3-(2-chlorophenyl)-5-methyl-1,3-dihydroindol-2-one | 492430-77-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-chloro-3-(2-chlorophenyl)-5-methyl-1,3-dihydroindol-2-one
• CAS: 492430-77-0
• 化学式: C₁₅H₁₁Cl₂NO
• 分子量: 292.164
• InChiKey: BSXWIYMVXQUHMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-chloro-3-(2-chlorophenyl)-5-methyl-1,3-dihydroindol-2-one 在 溴 作用下， 以 二氯甲烷 为溶剂， 生成 3-bromo-6-chloro-3-(2-chlorophenyl)-5-methyl-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use

  摘要：

  这项发明涉及以下公式的化合物：1，以及与矿物酸或有机酸形成的盐，以及具有亲和力和选择性作用于精氨酸加压素V1b受体和/或催产素受体的溶剂化合物和/或水合物，此外，对于某些化合物，还具有对V1a受体的亲和力。该发明还涉及制备它们的过程，对于制备它们有用的公式（IV）的中间化合物，含有它们的药物组合物以及它们用于制备药品的用途。

  公开号：

  US20040180878A1
• 作为产物：
  描述：

  2-氯苯乙酸甲酯 在 铁粉 、 溶剂黄146 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 6-chloro-3-(2-chlorophenyl)-5-methyl-1,3-dihydroindol-2-one
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists

  摘要：

  The ghrelin receptor is a G-protein-coupled receptor (GPCR) widely expressed in the brain, stomach and the intestine. It was firstly identified during studies aimed to find synthetic modulators of growth hormone (GH) secretion. GHSR and its endogenous ligand ghrelin were found to be involved in hunger response. Through food intake regulation, they could affect body weight and adiposity. Thus GHSR antagonists rapidly became an attractive target to treat obesity and feeding disorders. In this study we describe the biological properties of new indolinone derivatives identified as a new, chiral class of ghrelin antagonists. Their synthesis as well as the structure-activity relationship will be discussed herein. The in vitro identified compound 14f was a potent GHSR1a antagonist (IC50 = 7 nM). When tested in vivo, on gastric emptying model, 14f showed an inhibitory intrinsic effect when given alone and it dose dependently inhibited ghrelin stimulation. Compound 14f also reduced food intake stimulated both by fasting condition (high level of endogenous ghrelin) and by icv ghrelin. Moreover this compound improved glucose tolerance in ipGTT test. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.018

文献信息

• Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
  申请人：——

  公开号：US20040180878A1

  公开（公告）日：2004-09-16

  The invention relates to compounds of formula: 1 and also to the salts thereof with mineral or organic acids, and the solvates and/or hydrates thereof, with affinity for and selectivity towards the arginine-vasopressin V 1b receptors and/or for the ocytocin receptors and, furthermore, for certain compounds, affinity for the V 1a receptors. The invention also relates to the process for preparing them, to the intermediate compounds of formula (IV) that are useful for preparing them, to pharmaceutical compositions containing them and to their use for preparing medicinal products.

  这项发明涉及以下公式的化合物：1，以及与矿物酸或有机酸形成的盐，以及具有亲和力和选择性作用于精氨酸加压素V1b受体和/或催产素受体的溶剂化合物和/或水合物，此外，对于某些化合物，还具有对V1a受体的亲和力。该发明还涉及制备它们的过程，对于制备它们有用的公式（IV）的中间化合物，含有它们的药物组合物以及它们用于制备药品的用途。
• DERIVES DE 1-PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOL-2-ONE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：SANOFI-SYNTHELABO

  公开号：EP1419150A2

  公开（公告）日：2004-05-19
• US7119086B2
  申请人：——

  公开号：US7119086B2

  公开（公告）日：2006-10-10
• [EN] PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE<br/>[FR] DERIVES DE 1-PHENYLSULFONYL-1,3-DIHYDRO-2H-INDOL-2-ONE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：SANOFI SYNTHELABO

  公开号：WO2003008407A2

  公开（公告）日：2003-01-30

  L'invention concerne des composés de formule (1),ainsi que leurs sels avec des acides ou organiques, leurs et/ou leur hydrates, présentant une affinité et une sélectivité pour les récepteurs V1b de l'arginine-vasopressine et/ou pour les récepteurs de l'ocytocine et, de plus, pour certains composés une affinité pour les récepteurs Vla. L'invention conceme également leur procédé de préparation, les composés intermédiaires de formule (IV) utiles pour leur préparation, les compositions pharmaceutiques les contenant et leur utilisation pour la préparation de médicaments.
• Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists
  作者：Letizia Puleo、Pietro Marini、Roberta Avallone、Marco Zanchet、Silvio Bandiera、Marco Baroni、Tiziano Croci

  DOI：10.1016/j.bmc.2012.07.018

  日期：2012.9

  The ghrelin receptor is a G-protein-coupled receptor (GPCR) widely expressed in the brain, stomach and the intestine. It was firstly identified during studies aimed to find synthetic modulators of growth hormone (GH) secretion. GHSR and its endogenous ligand ghrelin were found to be involved in hunger response. Through food intake regulation, they could affect body weight and adiposity. Thus GHSR antagonists rapidly became an attractive target to treat obesity and feeding disorders. In this study we describe the biological properties of new indolinone derivatives identified as a new, chiral class of ghrelin antagonists. Their synthesis as well as the structure-activity relationship will be discussed herein. The in vitro identified compound 14f was a potent GHSR1a antagonist (IC50 = 7 nM). When tested in vivo, on gastric emptying model, 14f showed an inhibitory intrinsic effect when given alone and it dose dependently inhibited ghrelin stimulation. Compound 14f also reduced food intake stimulated both by fasting condition (high level of endogenous ghrelin) and by icv ghrelin. Moreover this compound improved glucose tolerance in ipGTT test. (C) 2012 Elsevier Ltd. All rights reserved.